OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
January 29, 2025
Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
February 15, 2022
Related Post
-
-
HOPE Therapeutics(TM), Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition
January 28, 2025
-
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
January 28, 2025
-
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025
January 17, 2025